INMD InMode Ltd.
USHealthcareAs of 2026-07-10 16:00
Why INMD matters now
InMode Ltd. (INMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.28 with +1.80% on the session and $878.3M in market capitalization; recent performance reads 1-month -4.08% and YTD -8.78%.
The latest financial table shown here is Q1 2026, with revenue of $82.0M, net income of $11.6M, and EPS of $0.18. Investors can compare that operating picture with valuation signals such as P/E 9.14 and FCF yield 11.1%.
The latest indexable market news headline is "InMode Confirms Receipt of Unsolicited Proposal" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $18.00; recent insider activity includes Moshe Itzkovich filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
9.14
PEG
—
P/B
1.28
P/S
2.17
EV/EBITDA
4.13
DCF Value
$36.01
FCF Yield
11.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.8%
Operating Margin
21.3%
Net Margin
23.3%
ROE
13.3%
ROA
11.6%
ROIC
10.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $82.0M | $11.6M | $0.18 |
| Q4 2025 | $103.9M | $27.0M | $0.42 |
| FY 2025 | $370.5M | $93.8M | $1.43 |
| Q3 2025 | $93.2M | $21.9M | $0.34 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$18.00
Target (Median)
$18.00
Target Range
$17.00 - $19.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
IL
Exchange
—
Beta
1.93
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.